Fulvestrant

Evidence Level: L5 Predicted Indications: 50

Quick Overview

Item Value
Drug Name Fulvestrant
DrugBank ID DB00947
Brand Names (EU) Faslodex
Evidence Level L5
Predicted Indications 50
Top Prediction Score 99.91%

Approved Indication (EMA)

Faslodex is indicated as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, or with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breas

Predicted New Indications

TxGNN model predictions for potential drug repurposing:

Rank Indication Score Source
1 HIV infectious disease 99.91% DL
2 multiple endocrine neoplasia 99.85% DL
3 simian immunodeficiency virus infection 99.83% DL
4 feline acquired immunodeficiency syndrome 99.83% DL
5 neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter 99.82% DL
6 rheumatoid arthritis 99.58% DL
7 acne (disease) 99.37% DL
8 brachydactyly-syndactyly syndrome 99.29% DL
9 hemoglobinopathy 99.29% DL
10 colobomatous microphthalmia-rhizomelic dysplasia syndrome 99.16% DL
11 psoriasis 99.15% DL
12 pyropoikilocytosis, hereditary 99.07% DL
13 beta-thalassemia with other manifestations 99.04% DL
14 partial deletion of the short arm of chromosome 16 99.02% DL
15 oral candidiasis 98.96% DL
16 hemolytic anemia due to glucophosphate isomerase deficiency 98.92% DL
17 homozygous familial hypercholesterolemia 98.83% DL
18 pyruvate kinase deficiency of red cells 98.75% DL
19 obsolete familial combined hyperlipidemia 98.73% DL
20 commissural lip fistula 98.72% DL

Showing top 20 of 50 predictions.

About TxGNN Predictions

Prediction Sources

Source Description
KG Knowledge Graph - Network topology-based associations
DL Deep Learning - Neural network score prediction

Evidence Levels

Level Definition
L1 Multiple Phase 3 RCTs / Systematic Reviews
L2 Single RCT or multiple Phase 2 trials
L3 Observational studies / Large case series
L4 Preclinical / Mechanistic / Case reports
L5 AI prediction only (current)

Clinical Validation Needed

Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.

Next Steps for Validation

  1. Literature Review: Search PubMed for existing evidence
  2. Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
  3. Mechanistic Analysis: Evaluate biological plausibility
  4. Preclinical Studies: Conduct in vitro/in vivo validation
  5. Clinical Trials: Design and conduct human studies

Data Access

Citation

If using this data, please cite:

@article{huang2023txgnn,
  title={A foundation model for clinician-centered drug repurposing},
  author={Huang, Kexin and others},
  journal={Nature Medicine},
  year={2023},
  doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.